Periodic Reporting for period 1 - STARPAC (STING immune activation and regulation by phosphatidylinositol 4-phosphate-associated components)
Reporting period: 2021-09-01 to 2023-08-31
STING activation is a tightly regulated multistep process that is aimed to prevent unwanted activation (which could lead to auto-inflammatory diseases) but at the same time must robustly activate the immune system in case of a real threat. How STING is regulated is not well understood. A better understanding of STING regulation will provide new targets to combat a wide variety of diseases, including auto-inflammatory conditions, cancer, and ageing.
In this project, we investigated how STING is regulated by phosphatidyl inositol-4 phosphate (PI4P), a lipid present at specific locations within the cell. In addition, we investigated how manipulating PI4P with (FDA-approved) drugs can redirect the immune response by STING. Finally, we tested whether viruses that use PI4P for replication (such as rhinoviruses) can tamper with STING activation by changing the intracellular distribution of PI4P.
Conclusion of the action
We found that targeting PI4P and PI4P-associated factors can alter immune activation by affecting the intracellular distribution of STING. Furthermore, we show (FDA-approved) compounds that target PI4P can dampen or promote immune activation by STING, and we thus provide novel therapeutic targets for clinically relevant diseases.
We also investigated the effect of viral proteins that target PI4P for virus replication, including the 3A proteins of rhinoviruses. Although we did not find an effect of these proteins on STING activation, we observed that certain rhinovirus strains depend on STING for replication. This preliminary data has instigated a new research line aimed at deciphering this surprising proviral role of STING.
Finally, this project revealed the unexpected finding that rhinoviruses hijack the antiviral protein STING to promote rhinovirus replication. This may ultimately lead to new antiviral compounds that reduce or prevent infections with this group of clinically relevant viruses.